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Active tobacco Smoking impairs 
cardiac Systolic function
tom Hendriks  1, Randy van Dijk1, najod A. Alsabaan1 & pim van der Harst  1,2*
Tobacco smoking is a well-established risk factor for cardiovascular disease, but its direct effect on 
myocardial structure and function remains unclear. This study investigated the effects of smoking 
using a nested matched case-control study design. 5,668 participants of the UK Biobank study who 
underwent cardiovascular magnetic resonance imaging were screened for inclusion. 102 smokers 
(56 males) with a median age of 56 years were matched to non-smokers based on sex, age, and body 
surface area. Manual post-processing and feature tracking analyses were performed to determine 
left ventricular (LV) and right ventricular (RV) structure and function measures. Linear regression 
analyses were performed to determine the effect of tobacco smoking on imaging measures. Tobacco 
smoking was associated with increased LV and RV end-systolic volume (4.98 ± 2.08 mL, 5.19 ± 2.62 mL, 
p = 0.018, 0.049 respectively), reduced LV and RV ejection fraction (β: −2.21 ± 0.82%, −2.06 ± 0.87%, 
p = 0.007, 0.019 respectively), and reduced absolute measures of LV peak global longitudinal, radial, 
and circumferential strain (β: 0.86 ± 0.30%, −2.52 ± 0.99%, 1.05 ± 0.32%, P = 0.004, 0.011, 0.001 
respectively). Effect sizes were larger in daily smokers compared to occasional smokers. In a general 
caucasian population without known clinical cardiovascular disease, active tobacco smoking was dose 
dependently associated with impaired cardiac systolic function.
Tobacco smoking is associated with an increased incidence of cardiovascular diseases, including myocardial 
infarction, vascular stroke, peripheral artery disease, and heart failure1–3. Pathophysiological effects of tobacco 
smoking include sympathomimetic effects, reduced oxygen supply to the organs, inflammation, endothelial dys-
function and a pro-thrombotic state4.
Large epidemiological studies focusing on the effects of cardiac risk factors on cardiac structure and function 
indicate an association of tobacco smoking with increased left ventricular (LV) mass and reduced LV systolic 
function5–8. However, other studies show conflicting results9,10. Most aforementioned studies were performed 
in populations with high prevalence of possible confounding factors such as hypertension, diabetes and obesity. 
Cardiovascular magnetic resonance imaging (CMR) is the gold standard for both structural and functional car-
diac assessment, as well as tissue characterization11. Advances in imaging post-processing have made it feasible 
to assess more subtle changes in cardiac contractility using feature tracking analysis to derive measures of myo-
cardial strain12,13.
The aim of our study was to determine the effects of tobacco smoking on cardiac structure and function using 
CMR as the imaging modality of choice.
Results
Study population. Baseline characteristics are presented in Table 1. In total, 204 participants were included 
in this study. Mean age of the study population was 58 ± 8 years and 112 subjects (55%) were male. Among 
the 102 smokers, 64 (63%) were daily smokers and 38 (37%) were occasional smokers. Income category and 
weekly alcohol units were significantly different between groups. Intraobserver variability in determining imag-
ing measures is presented in Table 2. Smokers had significantly lower mean values of LV ejection fraction (LVEF, 
58.6 ± 6.2% vs. 60.6 ± 4.6%, P = 0.011), RVEF (58.3 ± 6.5% vs. 60.5 ± 6.4%, P = 0.019), LV peak global longitu-
dinal strain (−15.6 ± 2.2% vs. −16.2 ± 2.0%, P = 0.024), radial strain (34.8 ± 7.8% vs. 37.1 ± 6.8%, P = 0.024), 
and circumferential strain (−19.3 ± 2.6% vs. −20.3 ± 2.2%, P = 0.004), compared with non-smokers. Figure 1 
demonstrates the difference in distribution of LVEF between smokers and non-smokers, which is most distinct 
in subjects that smoke on a daily basis.
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Effects of tobacco smoking. Results of the univariate and multivariable regression analyses are presented 
in Table 3. Active tobacco smoking was a significant predictor of impaired LV and RV systolic function, with 
regard to EF (β: −2.21 ± 0.82%, −2.06 ± 0.87%, P = 0.007, 0.019 respectively) as well as LV myocardial peak 
global longitudinal strain (GLS), peak global radial strain (GRS) and peak global circumferential strain (GCS) (β: 
0.86 ± 0.30%, −2.52 ± 0.99%, 1.05 ± 0.32%, P = 0.004, 0.011, 0.001 respectively), both in univariate linear regres-
sion analyses and after further adjustment for matching parameters and possible confounders. Tobacco smoking 
was also associated with a higher LV and RV end-systolic volume (ESV) after correcting for multiple confounding 
variables (β: 4.98 mL, 5.19 mL, P = 0.018, 0.049 respectively). Linear regression analyses were repeated in daily 
smokers and occasional smokers separately (Table 4). In occasional smokers (N = 38), none of the observed 
Non-smokers 
(N = 102) Smokers (N = 102) P
Male sex 56 (54.9%) 56 (54.9%) 1.00
Age, years 56.50 (51.24, 64.48) 56.45 (51.41, 64.05) 0.99
Weight, kg 71.75 (9.92) 72.55 (9.84) 0.56
Height, cm 171.33 (8.67) 170.76 (8.47) 0.64
Body mass index, kg/m2 24.39 (2.42) 24.84 (2.49) 0.19
Body surface area, m2 1.84 (0.16) 1.84 (0.16) 0.85
Waist hip ratio 0.85 (0.07) 0.86 (0.07) 0.29
Systolic blood pressure, mmHg 128.24 (17.06) 125.85 (14.99) 0.29
Diastolic blood pressure, mmHg 78.56 (8.84) 78.56 (8.08) 1.00
Pulse pressure, mmHg 49.68 (11.53) 47.29 (10.30) 0.12
Heart rate during CMR, bpm 61.60 (10.53) 63.22 (10.24) 0.27
Hypertension 24 (23.5%) 22 (21.6%) 0.74
Antihypertensive medication 13 (12.7%) 9 (8.8%) 0.37
Hyperlipidemia 15 (14.7%) 24 (23.5%) 0.11
Diabetes mellitus 3 (2.9%) 5 (4.9%) 0.47
Chronic obstructive pulmonary disease 23 (22.5%) 18 (17.6%) 0.38
Townsend deprivation index 0.01 (0.94) 0.15 (1.18) 0.37
Average total household income before tax
0.022
<18,000 4 (3.9%) 14 (13.7%)
18,000–30,999 17 (16.7%) 28 (27.5%)
31,000–51,999 33 (32.4%) 18 (17.6%)
52,000–100,000 29 (28.4%) 25 (24.5%)
>100,000 9 (8.8%) 7 (6.9%)
Unknown 10 (9.8%) 10 (9.8%)
Alcohol intake, per week 9.60 (2.26, 15.70) 13.20 (3.90, 24.60) 0.020
Table 1. Baseline characteristics. Normally distributed continuous variables are presented as mean (standard 
deviation) and non-normally distributed variables as median (interquartile range). Categorical data are 




LV end-diastolic volume 0.99
LV end-systolic volume 0.90
LV ejection fraction 0.77
LV cardiac output 0.93
LV mass to volume ratio 0.88
RV end-diastolic volume 0.99
RV end-systolic volume 0.97
RV ejection fraction 0.85
LV peak global longitudinal strain 0.93
LV peak global radial strain 0.99
LV peak global circumferential 
strain 0.99
Table 2. Intraobserver variability. LV, left ventricular; RV, right ventricular.
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effects of tobacco smoking on imaging biomarkers remained significant (P > 0.05), whereas larger effect sizes and 
higher significance was observed in the group of daily smokers (N = 64).
Discussion
In this nested matched case-control study, we observed a significant association between active tobacco smoking 
and impaired systolic LV and RV function, in terms of EF as well as myocardial strain measures. The observed 
associations were mostly driven by daily tobacco smokers.
Previous studies reporting on the effects of tobacco smoking on cardiac structure and function have shown 
contradictory results5–10. Most studies observed an association between tobacco smoking and reduced systolic 
function and increased LV mass. The heterogeneity of these study populations possibly influence and obscure the 
independent effect of tobacco smoking on cardiac structure and function. By using strict in- and exclusion cri-
teria, we selected a relatively healthy population of UK Biobank participants free of major cardiovascular disease 
and with BMI and blood pressures within normal ranges. We believe that our pre-selection combined with the 
further correction in our regression models more clearly show the possible independent effects of active tobacco 
smoking. We were also able to assess more subtle changes in cardiac contractility using strain analysis. We 
observed that smoking status significantly impaired systolic LV and RV function by increasing ESV, and reducing 
EF and absolute measures of LV myocardial strain. This effect was mostly driven by daily smokers. Although 
the study was not designed for this purpose, no significant effect of occasional smoking on cardiac structure 
and function was found. In our study, tobacco smoking was not associated with increased LV mass, which was 
observed in several previous studies5–7,10. A possible reason could be that LV hypertrophy has a very multifactorial 
etiology (e.g. metabolic, immunologic, vascular) and we selected our study population to be relatively healthy.
Several large epidemiological studies have suggested tobacco smoking to be a risk factor for impaired car-
diac function and heart failure1,14, assumed to be driven by myocardial infarctions. Our results seem to indicate 
that there is a direct relationship between tobacco smoking and subclinical impaired systolic function. Chronic 
Figure 1. Distribution of left ventricular ejection fraction in smokers vs. non-smokers, and daily smokers vs. 
non-smokers.
Univariate Model 1* Model 2†
Beta SE P Beta SE P Beta SE P
LV mass (g) 1.17 2.75 0.67 0.93 1.75 0.60 2.94 1.82 0.11
LV end-diastolic volume (mL) −0.47 4.66 0.92 −0.74 3.39 0.83 3.26 3.29 0.32
LV end-systolic volume (mL) 3.02 2.58 0.24 2.91 2.00 0.15 4.98 2.08 0.018
LV ejection fraction (%) −1.97 0.77 0.011 −1.96 0.74 0.009 −2.21 0.82 0.007
LV cardiac output (L/min) −0.08 0.15 0.60 −0.08 0.13 0.52 −0.08 0.14 0.54
LV mass to volume ratio (g/mL) 0.014 0.012 0.27 0.013 0.011 0.24 0.014 0.011 0.20
RV end-diastolic volume (mL) 0.50 5.39 0.93 0.20 3.88 0.96 3.87 4.09 0.35
RV end-systolic volume (mL) 3.61 3.21 0.26 3.47 2.37 0.15 5.19 2.62 0.049
RV ejection fraction (%) −2.14 0.90 0.019 −2.13 0.80 0.008 −2.06 0.87 0.019
LV peak global longitudinal strain (%) 0.67 0.29 0.024 0.66 0.29 0.022 0.86 0.30 0.004
LV peak global radial strain (%) −2.34 1.03 0.023 −2.33 0.90 0.011 −2.52 0.99 0.011
LV peak global circumferential strain (%) 0.98 0.33 0.004 0.98 0.29 0.001 1.05 0.32 0.001
Table 3. Linear regression results; effects of smoking on measures of cardiac structure and function. LV, 
left ventricular; RV, right ventricular. Reported are unstandardized regression coefficients for active tobacco 
smoking. *Corrected for body surface area, age, sex. †Corrected for body surface area, age, sex, diastolic blood 
pressure, systolic blood pressure, antihypertensive medication, hyperlipidemia, diabetes mellitus, income 
category, and alcohol intake.
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exposure to tobacco smoking has a direct effect on the microvascular compartment, which could be the cause 
of the observed subtle functional systolic impairment. Tobacco smoke consists of more than 5.000 toxic and 
carcinogenic chemicals15. The (chronic) exposure to these toxic chemicals have potentially devastating effects 
on cardiac tissue, causing a complex cascade of inflammation, endothelial injury, dysfunction, cell death and 
fibro-fatty replacement16. Biochemically, tobacco smoking has been associated with increased levels of biomark-
ers for increased wall stress and myocardial injury such as NT-proBNP and high-sensitive troponin T17. Former 
heavy smokers have an increased risk of developing heart failure that former light smokers do not have18,19, sug-
gesting permanent myocardial injury related to frequency of smoking or cumulative exposure to tobacco smoke. 
We studied individuals without known myocardial infarction. However, we cannot rule out that the observed 
impairment of systolic function is due to the effects of myocardial ischemia resulting from subclinical coro-
nary atherosclerosis, as subjects did not undergo coronary computed tomography or conventional angiography. 
Further research is needed to assess how tobacco smoking affects diastolic function, and to unravel the mecha-
nisms behind the observed link between tobacco smoking and depressed systolic function.
Strengths and Limitations
One of the strengths of this study is its design, a nested matched case control study in a relatively healthy pop-
ulation allows for an unbiased interpretation of the effect of tobacco smoking with little confounding. Other 
strengths include the use of CMR feature tracking analyses. There are some limitations to this study that should 
be highlighted. This study was a retrospective analysis of participants included in the UK Biobank study. The par-
ticipants received extensive questionnaires during multiple visits, but there was insufficient information on the 
extent of tobacco smoke exposure (e.g. pack years) and daily number of cigarettes to include these parameters in 
the analysis. To address possible confounding we performed regression analysis with correction for confounders 
known from previous studies. However, there might be residual confounding due to variables other than those 
included in the analysis, such as a difference in physical activity between smokers and non-smokers, and the 
observed relationship between tobacco smoking and impaired systolic function should not be interpreted as 
direct causality.
conclusions
In this nested matched case control study within Caucasian subjects of the UK Biobank free of major cardiovas-
cular disease, active tobacco smoking was dose dependently associated with impaired cardiac systolic function as 
indicated by alterations in end-systolic volume, ejection fraction, and myocardial strain measures. Our findings 
suggest that smoking cause subclinical changes in ventricular function, even in the absence of evident clinical 
cardiac disease. Further research is needed to unravel the mechanisms behind the link between tobacco smoking 
and impaired systolic function.
Methods
The data for this study is publicly available to registered investigators of the UK Biobank.
Study population. We performed a nested matched case-control study including 5,668 UK Biobank subjects 
who underwent CMR assessment. The UK Biobank is a major national health resource including approximately 
500,000 participants aged 40–69 years20. Written informed consent was obtained in all subjects. UK Biobank’s 
research ethics committee and Human Tissue Authority research tissue bank approvals mean that researchers 
wishing to use the resource do not need separate ethics approval. Baseline visits took place between 2006–2010, in 
which subjects received elaborate touchscreen questionnaires, underwent anthropometric and vital signs meas-
urements, and were interviewed by a trained nurse to determine medical history and medication use. In addition, 
Occasional tobacco smoking 
(N = 38) Daily tobacco smoking (N = 64)
Beta SE P Beta SE P
LV mass (g) 2.97 2.39 0.22 2.92 2.07 0.16
LV end-diastolic volume (mL) 2.22 4.32 0.61 3.92 3.73 0.30
LV end-systolic volume (mL) 1.30 2.70 0.63 7.28 2.33 0.002
LV ejection fraction (%) −0.39 1.05 0.71 −3.35 0.91 <0.001
LV cardiac output (L/min) −0.39 0.18 0.83 −0.11 0.16 0.47
LV mass to volume ratio (g/mL) 0.014 0.015 0.35 0.015 0.013 0.25
RV end-diastolic volume (mL) 5.45 5.39 0.31 2.89 4.65 0.54
RV end-systolic volume (mL) 4.92 3.45 0.16 5.36 2.98 0.073
RV ejection fraction (%) −1.47 1.14 0.20 −2.43 0.99 0.015
LV peak global longitudinal strain (%) 0.26 0.38 0.50 1.23 0.33 <0.001
LV peak global radial strain (%) −1.85 1.30 0.15 −2.94 1.12 0.009
LV peak global circumferential strain (%) 0.75 0.41 0.072 1.24 0.36 0.001
Table 4. Linear regression results; comparison of daily with occasional tobacco smoking. LV, left ventricular; 
RV, right ventricular. Reported are unstandardized regression coefficients, corrected for body surface area, age, 
sex, diastolic blood pressure, systolic blood pressure, antihypertensive medication, hyperlipidemia, diabetes 
mellitus, income category, and alcohol intake.
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hospital episode statistics were collected. In 2014, the UK Biobank started with imaging visits, with the aim to 
perform CMR assessments in 100,000 subjects. During imaging visits, most procedures from baseline visit were 
repeated.
Baseline characteristics of all participants that were included in the current study were obtained at the imag-
ing visit. Daily smokers were defined as subjects who answered “yes, on most or all days” to the question “do you 
smoke tobacco now?” during the imaging visit, and occasional smokers were defined as subjects who answered 
“only occasionally” to the question “do you smoke tobacco now?” and in addition had to have smoked at least 100 
times in their lifetime. Body surface area (BSA) was calculated using the equation proposed by Du Bois and Du 
Bois21. Blood pressure was defined as the average of two automated blood pressure measurements. Automated 
measurements were modified based on the method described by Stang et al.22. Definitions of chronic obstruc-
tive pulmonary disease, hypertension, diabetes mellitus and hypercholesterolemia included medication use. 
Townsend Deprivation Index (TDI, a proxy for socioeconomic status) was determined at baseline visit by the UK 
Biobank and inverse rank normalized.
Exclusion criteria were major cardiovascular disease (defined as stroke, transient ischemic attack, cardiac sur-
gery, percutaneous cardiac intervention, pacemaker/implantable cardioverter defibrillator, cardiomyopathy, heart 
failure, myocardial infarction, peri-/myocarditis, arrhythmia, cardiac arrest, valvular disease, pulmonary arterial 
hypertension, thromboembolism, coronary artery disease, non-cardiac arterial disease, or atherosclerosis), renal 
failure, cancer or chemotherapy, former smokers (daily or almost daily) with at least >100 smoked cigarettes in 
their lifetime, BMI < 16 or >30, systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg, 
and non-Caucasian ethnicity. After applying exclusion criteria, 139 active smokers and 1899 non-smokers were 
identified. Smokers were matched in a 1:1 ratio with non-smokers based on sex, age (rounded to the nearest 
year) and BSA (rounded to the nearest decimal). After matching, image quality of CMR assessment was assessed, 
blinded to study group. If image quality was deemed too poor due to missing short axis stacks, major artifacts or 
poor axis alignment, smokers were excluded and non-smokers were replaced with a new match, if possible. 14 
smokers were not able to be matched with a control and 23 smokers were excluded due to poor image quality, 
leaving a total of 102 active smokers matched with non-smokers.
image acquisition. The UK Biobank CMR protocol has been published previously23. In brief, a 20-min 
CMR protocol was used without administration of contrast agents. A steady-state free precession (SSFP) pulse 
sequence was used on a 1.5 Tesla scanner (MAGNETOM Aera, Syngo Platform VD13A, Siemens Healthcare, 
Erlangen, Germany) for the acquisition of a short axis cine stack covering the complete left and right ventricle, 
and a 2-chamber view (2CV), 3-chamber view (3CV), and 4-chamber view (4CV) long axis cine series.
image post processing. Manual post-processing analyses were performed using cvi42 post-processing soft-
ware (Circle Cardiovascular Imaging Inc., Calgary, Alberta, Canada). LV and RV endocardial and LV epicardial 
contours were drawn at end-diastolic and end-systolic phases in short axis cine images. LV mass was determined 
at end diastolic phase, papillary muscles were excluded from LV mass. The cvi42 tissue tracking plugin in beta 
release 5.3.0.821 was used to determine LV myocardial strain measures. LV endo- and epicardial contours at end 
diastolic phase in short axis cine images were used to determine peak GRS and peak GCS. To determine peak 
GLS, LV endo- and epicardial contours were drawn at end-diastolic phase in long axis cine images (2CV, 3CV, 
4CV). All post processing analyses were performed by one experienced observer, blinded to study group, accord-
ing to contemporary consensus recommendations24.
Statistical analysis. Differences in baseline characteristics between smokers and non-smokers were com-
pared using an independent t-test in case of normally distributed continuous variables, a Wilcoxon rank-sum test 
in case of non-normally distributed continuous variables, and a Pearson’s chi-squared test in case of categorical 
variables. Intraobserver variability in imaging measures was assessed using intraclass correlation coefficients. 
The effect size of tobacco smoking on imaging measures was assessed using linear regression analyses. A missing 
value of alcohol intake per week was imputed with the median value of the study population. Three linear regres-
sion models were used; simple univariate linear regression, a multivariable model (Model 1) adjusting for the 
matching parameters (age, sex, and BSA), and a multivariable model (Model 2) additionally adjusting for baseline 
characteristics that were significantly different between groups (income and alcohol consumption) and other 
cardiovascular risk factors (BMI, diastolic blood pressure, systolic blood pressure, antihypertensive medication, 
hyperlipidemia, and diabetes mellitus). Multivariable analysis using Model 2 was repeated using a categorical 
smoking variable to test independently for the effects of daily tobacco smoking and occasional tobacco smoking. 
A significance level (α) <0.05 was considered statistically significant. All statistical analyses were performed 
using Stata/SE version 15.1.
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